Physician profile
Donna L Shine
NPI 1417978404
$1,968.20
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $459 · 2020: $178 · 2021: $1,150 · 2022: $181.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $660.33 | 2019-2022 | |
| Aspira Women'S Health INC | $151.88 | 2021 | |
| Daiichi Sankyo INC. | $132.96 | 2019-2022 | |
| Exeltis, USA INC. | $106.90 | 2020-2022 | |
| Ethicon US, LLC | $102.14 | 2021 | |
| Gen-Probe Sales & Service, INC. | $89.23 | 2021 | |
| Myovant Sciences INC. | $75.11 | 2021-2022 | |
| Amgen INC. | $72.73 | 2019-2020 | |
| Hologic Sales and Service, LLC | $71.62 | 2019-2022 | |
| Therapeuticsmd, INC. | $59.96 | 2019-2020 | |
| Avion Pharmaceuticals | $56.93 | 2020-2022 | |
| Coopersurgical, INC. | $47.71 | 2019-2022 | |
| Allergan, INC. | $41.66 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.21 | 2019 | |
| Mayne Pharma Commercial LLC | $28.84 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Duchesnay USA Incorporated | $28.14 | 2019 | |
| Agile Therapeutics, INC. | $27.97 | 2021 | |
| Roche Diagnostics Corporation | $24.22 | 2019 | |
| Evofem Biosciences, INC. | $23.37 | 2021 | |
| Lupin INC. | $22.62 | 2021 | |
| Merck Sharp & Dohme LLC | $22.18 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.95 | 2019 | |
| Pfizer INC. | $15.15 | 2019 | |
| Axonics, INC. | $14.99 | 2021 | |
| Olympus America INC. | $14.22 | 2019 | |
| Mylan Pharmaceuticals INC. | $11.73 | 2019 | |
| Amag Pharmaceuticals, INC. | $11.45 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Shine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.